左卡尼汀联合黄芪注射液治疗急性病毒性心肌炎的临床分析

目的探讨左卡尼汀联合黄芪注射液治疗急性病毒性心肌炎的临床效果。方法将急性病毒性心肌炎患者98例随机分为观察组与对照组,每组各49例,对照组给予常规治疗,观察组在对照组基础上加用左卡尼汀与黄芪注射液,比较两组的疗效。结果在临床疗效上,观察组总有效率为95.92%,对照组为75.51%,差异有统计学意义（P〈0.05）;在心电图疗效上观察组总有效率为91.84%,对照组则为69.39%,差异有统计学意义（P〈0.05）;观察组的血清肌酸磷酸酶同工酶（CK-MB）、肌钙蛋白T（cTnT）、肌钙蛋白Ⅰ（cTnⅠ）、C反应蛋白（CRP）及脑钠肽（BNP）治疗前与治疗后比较,差异有统计学意义（P〈0.05）;观察组CK-MB、cTnT、cTnⅠ、CRP及BNP治疗后的改善与对照组治疗后比较,差异有统计学意义（P〈0.05）。结论左卡尼汀联合黄芪注射液治疗急性病毒性心肌炎疗效显著,不良反应轻微,值得临床推广。

Clinical analysis of Levocarnitine combined with Astragalus Membranaceus Injection in the treatment of acute viral myocarditis

Objective To investigate the clinical effect of Levocarnitine combined with Astragalus Membranaceus Injection in the treatment of acute viral myocarditis.Methods 98 patients with acute viral myocarditis were randomly divided into the observation group and the control group,with 49 cases in each group.The patients in the control group were treated by conventional therapy,and on the basis of the control group,the observation group was treated by Levocarnitine and Astragalus Membranaceus Injection,and the clinical effects were compared.Results On he clinical effect,the total effective rate of the observation group was 95.92%,and the control group was 75.51%,with statistically significant difference(P < 0.05).And on the electrocardiogram effect,the total effective rate of the observation group was 91.84%,and the control group was 69.39%,with statistically significant difference(P < 0.05).The CK-MB,cTnT,cTnl,CRP and BNP of the observation group after treatment were all better than before treatment(P < 0.05).After treatment,the CK-MB,cTnT,cTnⅠ,CRP and BNP of the observation group were all better than the control group,there were statistically significant differences(P < 0.05).Conclusion The acute viral myocarditis treated by Levocarnitine and Astragalus Membranaceus Injection has marked effects,less untoward effect,which is worth of clinical application.